CY1122399T1 - Αγωνιστικοι παραγοντες δεσμευσης του υποδοχεα tnf - Google Patents
Αγωνιστικοι παραγοντες δεσμευσης του υποδοχεα tnfInfo
- Publication number
- CY1122399T1 CY1122399T1 CY20191101191T CY191101191T CY1122399T1 CY 1122399 T1 CY1122399 T1 CY 1122399T1 CY 20191101191 T CY20191101191 T CY 20191101191T CY 191101191 T CY191101191 T CY 191101191T CY 1122399 T1 CY1122399 T1 CY 1122399T1
- Authority
- CY
- Cyprus
- Prior art keywords
- competitive
- receptor binding
- tnf receptor
- binding factors
- binding agents
- Prior art date
Links
- 230000002860 competitive effect Effects 0.000 title 1
- 239000011230 binding agent Substances 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε παράγοντες δέσμευσης που δεσμεύονται σε υποδοχείς της υπεροικογένειας του TNF και πιο συγκεκριμένα παράγοντες δέσμευσης που δεσμεύονται σε τουλάχιστον δύο διαφορετικούς υποδοχείς της υπεροικογένειας του TNF, καθώς και στη χρήση τους στην ιατρική. Η παρούσα εφεύρεση αναφέρεται περαιτέρω σε μόρια νουκλεϊκού οξέος που κωδικοποιούν τέτοιους παράγοντες δέσμευσης, σε κύτταρα που περιλαμβάνουν τέτοια μόρια νουκλεϊκού οξέος και σε φαρμακευτικές συνθέσεις και κιτ.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2015050255 | 2015-01-08 | ||
PCT/EP2016/050308 WO2016110584A1 (en) | 2015-01-08 | 2016-01-08 | Agonistic tnf receptor binding agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122399T1 true CY1122399T1 (el) | 2020-11-25 |
Family
ID=55072677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191101191T CY1122399T1 (el) | 2015-01-08 | 2019-11-13 | Αγωνιστικοι παραγοντες δεσμευσης του υποδοχεα tnf |
Country Status (24)
Country | Link |
---|---|
US (3) | US10457735B2 (el) |
EP (3) | EP3242890B1 (el) |
JP (4) | JP6744326B2 (el) |
KR (3) | KR102238326B1 (el) |
CN (3) | CN111499752B (el) |
AU (2) | AU2016205974B2 (el) |
BR (1) | BR112017013189B1 (el) |
CA (2) | CA3224830A1 (el) |
CY (1) | CY1122399T1 (el) |
DK (2) | DK3242890T3 (el) |
ES (2) | ES2922398T3 (el) |
HR (2) | HRP20220811T1 (el) |
HU (2) | HUE059219T2 (el) |
LT (1) | LT3623386T (el) |
ME (1) | ME03576B (el) |
MX (2) | MX2017008917A (el) |
PL (2) | PL3242890T3 (el) |
PT (2) | PT3242890T (el) |
RS (2) | RS63384B1 (el) |
RU (1) | RU2723131C2 (el) |
SG (2) | SG11201704597WA (el) |
SI (2) | SI3623386T1 (el) |
WO (1) | WO2016110584A1 (el) |
ZA (1) | ZA201704797B (el) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014110601A1 (en) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
ME03666B (me) | 2014-03-28 | 2020-10-20 | Xencor Inc | Bispecifična antitela koja se vezuju za cd38 i cd3 |
EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
KR20170084326A (ko) | 2014-11-26 | 2017-07-19 | 젠코어 인코포레이티드 | Cd3 및 종양 항원과 결합하는 이종이량체 항체 |
US10259882B2 (en) | 2015-05-07 | 2019-04-16 | Agenus Inc. | Anti-OX40 antibodies |
US11447557B2 (en) | 2015-12-02 | 2022-09-20 | Agenus Inc. | Antibodies and methods of use thereof |
CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
PE20181535A1 (es) | 2015-12-16 | 2018-09-26 | Gritstone Oncology Inc | Identificacion, fabricacion y uso de neoantigeno |
JP2019523630A (ja) * | 2016-04-22 | 2019-08-29 | アリゲーター・バイオサイエンス・アーベー | Cd137に対する新規の二重特異性ポリペプチド |
EP4257613A3 (en) | 2016-06-14 | 2023-12-13 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
EP3475304B1 (en) | 2016-06-28 | 2022-03-23 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
CA3030636A1 (en) * | 2016-07-14 | 2018-01-18 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
WO2018045110A1 (en) * | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
EP3507306A1 (en) * | 2016-08-30 | 2019-07-10 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2018056821A1 (en) * | 2016-09-23 | 2018-03-29 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
WO2018134787A2 (en) | 2017-01-20 | 2018-07-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd137+ cells |
JP2020511959A (ja) * | 2017-03-29 | 2020-04-23 | グリコトープ ゲーエムベーハー | ヒト化抗cd40抗体 |
CA3070272A1 (en) | 2017-07-20 | 2019-01-24 | Aptevo Research And Development Llc | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
KR20200064062A (ko) | 2017-08-04 | 2020-06-05 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
EP3676294A4 (en) * | 2017-08-28 | 2021-12-22 | Systimmune, Inc. | ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF |
JP7227237B2 (ja) | 2017-10-10 | 2023-02-21 | グリットストーン バイオ インコーポレイテッド | ホットスポットを利用した新生抗原の特定 |
JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗pd−1配列を用いた二重特異性および単一特異性抗体 |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
AU2018373154A1 (en) | 2017-11-22 | 2020-07-02 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
AU2018390418B2 (en) | 2017-12-19 | 2023-12-21 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
EP3773911A2 (en) | 2018-04-04 | 2021-02-17 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
AU2019256539A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
US11845797B2 (en) | 2018-07-03 | 2023-12-19 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
AU2019355971A1 (en) | 2018-10-03 | 2021-05-06 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
CA3118789A1 (en) | 2018-11-06 | 2020-05-14 | Genmab A/S | Antibody formulation |
JP7463366B2 (ja) | 2018-11-20 | 2024-04-08 | タケダ ワクチン,インコーポレイテッド | 新規の抗ジカウイルス抗体及びその使用 |
CA3132185A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
SG11202110287QA (en) | 2019-04-24 | 2021-10-28 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
BR112022015151A2 (pt) | 2020-02-04 | 2022-12-20 | Genmab As | Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição |
US11940448B2 (en) | 2020-03-31 | 2024-03-26 | Seattle Children's Hospital | Proteomic screening for lysosomal storage diseases |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
CN112175080B (zh) * | 2020-10-22 | 2021-05-25 | 优睿赛思(武汉)生物科技有限公司 | 抗人白介素-6高亲和力兔单克隆抗体及应用 |
KR20230128482A (ko) | 2020-12-07 | 2023-09-05 | 젠맵 에이/에스 | 항체와 탁산의 조합 요법 |
IL305736A (en) | 2021-03-09 | 2023-11-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and CLDN6 |
CA3211334A1 (en) * | 2021-03-09 | 2022-09-15 | Yali FU | Multispecific binding agents against cd40 and cd137 in therapy |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
BR112023020832A2 (pt) | 2021-04-08 | 2023-12-19 | Marengo Therapeutics Inc | Moléculas multifuncionais ligadas a tcr e seus usos |
TW202315891A (zh) | 2021-06-21 | 2023-04-16 | 丹麥商珍美寶股份有限公司 | 結合劑給藥排程 |
WO2024050318A1 (en) * | 2022-08-27 | 2024-03-07 | H. Lee Moffitt Cancer Center And Research Institute | Cd40l 41bbl bispecific proteins |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP1482972A4 (en) * | 2001-11-20 | 2005-11-23 | Seattle Genetics Inc | TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES |
CN101023102B (zh) * | 2004-09-17 | 2013-05-29 | 霍夫曼-拉罗奇有限公司 | 抗-ox40l抗体 |
NZ591252A (en) * | 2006-03-17 | 2012-06-29 | Biogen Idec Inc | Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids |
GB0620894D0 (en) * | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
US20100136030A1 (en) | 2007-02-27 | 2010-06-03 | Lamhamedi-Cherradi Salah-Eddine | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
ES2667863T3 (es) | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
PL2201100T3 (pl) | 2007-09-14 | 2016-10-31 | Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu | |
EP2851374B1 (en) * | 2007-12-14 | 2017-05-03 | Bristol-Myers Squibb Company | Binding molecules to the human OX40 receptor |
US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
JP5782385B2 (ja) | 2009-02-17 | 2015-09-24 | ユーシービー ファーマ ソシエテ アノニム | ヒトox40に対する特異性を有する抗体分子 |
AU2011275749C1 (en) | 2010-07-09 | 2015-09-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to CD27 |
PT2663580T (pt) | 2011-01-10 | 2017-03-10 | Univ Zuerich | Terapêutica de associação incluindo anticorpos de ligação a antigénios associados a tumores |
EA036047B1 (ru) | 2011-07-11 | 2020-09-18 | Икнос Сайенсиз Са | Антитела, которые связываются с ox40, и их применение |
CN103946238B (zh) * | 2011-08-23 | 2016-10-12 | 德克萨斯州立大学董事会 | 抗ox40抗体及使用其的方法 |
GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
PT2976361T (pt) * | 2013-03-18 | 2018-10-19 | Janssen Pharmaceuticals Inc | Anticorpos anti-cd134 (ox40) humanizados e utilizações dos mesmos |
CA3030636A1 (en) * | 2016-07-14 | 2018-01-18 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
-
2016
- 2016-01-08 RS RS20220653A patent/RS63384B1/sr unknown
- 2016-01-08 ES ES19194817T patent/ES2922398T3/es active Active
- 2016-01-08 EP EP16700136.1A patent/EP3242890B1/en active Active
- 2016-01-08 EP EP19194817.3A patent/EP3623386B1/en active Active
- 2016-01-08 MX MX2017008917A patent/MX2017008917A/es active IP Right Grant
- 2016-01-08 BR BR112017013189-7A patent/BR112017013189B1/pt active IP Right Grant
- 2016-01-08 HR HRP20220811TT patent/HRP20220811T1/hr unknown
- 2016-01-08 KR KR1020177021592A patent/KR102238326B1/ko active IP Right Grant
- 2016-01-08 CN CN201911288299.4A patent/CN111499752B/zh active Active
- 2016-01-08 SI SI201631557T patent/SI3623386T1/sl unknown
- 2016-01-08 JP JP2017554647A patent/JP6744326B2/ja active Active
- 2016-01-08 SG SG11201704597WA patent/SG11201704597WA/en unknown
- 2016-01-08 PL PL16700136T patent/PL3242890T3/pl unknown
- 2016-01-08 AU AU2016205974A patent/AU2016205974B2/en active Active
- 2016-01-08 PL PL19194817.3T patent/PL3623386T3/pl unknown
- 2016-01-08 SI SI201630421T patent/SI3242890T1/sl unknown
- 2016-01-08 PT PT167001361T patent/PT3242890T/pt unknown
- 2016-01-08 CA CA3224830A patent/CA3224830A1/en active Pending
- 2016-01-08 RU RU2017127792A patent/RU2723131C2/ru active
- 2016-01-08 LT LTEP19194817.3T patent/LT3623386T/lt unknown
- 2016-01-08 DK DK16700136.1T patent/DK3242890T3/da active
- 2016-01-08 US US15/538,419 patent/US10457735B2/en active Active
- 2016-01-08 KR KR1020217009922A patent/KR102640769B1/ko active IP Right Grant
- 2016-01-08 HU HUE19194817A patent/HUE059219T2/hu unknown
- 2016-01-08 PT PT191948173T patent/PT3623386T/pt unknown
- 2016-01-08 ES ES16700136T patent/ES2755527T3/es active Active
- 2016-01-08 EP EP22167212.4A patent/EP4071176A3/en active Pending
- 2016-01-08 HU HUE16700136A patent/HUE048532T2/hu unknown
- 2016-01-08 WO PCT/EP2016/050308 patent/WO2016110584A1/en active Application Filing
- 2016-01-08 RS RS20191503A patent/RS59693B1/sr unknown
- 2016-01-08 KR KR1020247005611A patent/KR20240028548A/ko active Search and Examination
- 2016-01-08 CA CA2969888A patent/CA2969888A1/en active Pending
- 2016-01-08 ME MEP-2019-278A patent/ME03576B/me unknown
- 2016-01-08 DK DK19194817.3T patent/DK3623386T3/da active
- 2016-01-08 CN CN202311416068.3A patent/CN117843799A/zh active Pending
- 2016-01-08 CN CN201680005119.5A patent/CN109476761B/zh active Active
- 2016-01-08 SG SG10202003171TA patent/SG10202003171TA/en unknown
-
2017
- 2017-07-05 MX MX2020012240A patent/MX2020012240A/es unknown
- 2017-07-14 ZA ZA2017/04797A patent/ZA201704797B/en unknown
-
2019
- 2019-09-25 US US16/582,534 patent/US10927181B2/en active Active
- 2019-10-09 HR HRP20191824TT patent/HRP20191824T1/hr unknown
- 2019-11-13 CY CY20191101191T patent/CY1122399T1/el unknown
-
2020
- 2020-07-30 JP JP2020129222A patent/JP6950056B2/ja active Active
-
2021
- 2021-01-08 US US17/144,591 patent/US11814411B2/en active Active
- 2021-09-22 JP JP2021153986A patent/JP7390345B2/ja active Active
-
2022
- 2022-01-28 AU AU2022200571A patent/AU2022200571A1/en active Pending
-
2023
- 2023-04-04 JP JP2023060755A patent/JP7487376B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122399T1 (el) | Αγωνιστικοι παραγοντες δεσμευσης του υποδοχεα tnf | |
CY1124834T1 (el) | Αναστολεις της αλληλεπιδρασης της μηνινης-mll | |
AR125268A2 (es) | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos | |
CY1121934T1 (el) | Αντισωματα anti-fcrn | |
CY1122308T1 (el) | St2l ανταγωνιστες και μεθοδοι χρησης | |
CY1121462T1 (el) | Ακυλιωμενα αναλογα γλυκαγονης | |
CY1118014T1 (el) | Aνti-il-23 αντισωματα | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
EA201890443A1 (ru) | Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение | |
CY1118932T1 (el) | Τροποποιητες του σχετικου με ρετινοειδη ορφανου υποδοχεα γ (ror-γ) προς χρηση στην αγωγη εναντι αυτοανοσων και φλεγμονωδων νοσων | |
EA202192165A1 (ru) | Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы | |
DK3337824T3 (da) | Anti-bcma-antistoffer, bispecifikke antigen-bindende molekyler, som binder bcma og cd3, og anvendelse deraf | |
CY1123007T1 (el) | Υποκατεστημενα 4-αζαϊνδολια και χρηση αυτων ως ρυθμιστες υποδοχεα glun2b | |
CL2014001254A1 (es) | Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes. | |
MX2023000079A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento de sinusitis cronica con polipos nasales. | |
CY1117842T1 (el) | Πολυπεπτιδια μεταλλαγμενης il-2 | |
EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
EA201591478A1 (ru) | Биспецифические антитела против фно и ил-17 | |
CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
EA201391457A1 (ru) | Белки, связывающиеся с bcma (cd269/tnfrsf17) | |
EA201490644A1 (ru) | Терапевтические пептиды | |
BR112016024515A2 (pt) | proteínas do agonista do receptor trail de cadeia única | |
AR073072A1 (es) | Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano | |
CY1120751T1 (el) | Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων | |
CY1123615T1 (el) | Πολυσθενεις και πολυειδικες συντηγμενες πρωτεïνες που δεσμευουν τον dr5 |